Carbidopa/Levodopa Pharmacy Errors in Parkinson's Disease

被引:7
|
作者
Khadem, Nasim R. [1 ]
Nirenberg, Melissa J. [1 ]
机构
[1] Weill Cornell Med Coll, Dept Neurol & Neurosci, New York, NY USA
关键词
carbidopa/levodopa; healthcare utilization; Parkinson; outpatient; pharmacy error; prescription; ADVERSE DRUG EVENTS; MEDICATION ERRORS; LOOK-ALIKE; IMPACT; CARE;
D O I
10.1002/mds.23311
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Outpatient pharmacy errors are common, but little is known about their occurrence in Parkinson's disease (PD). We prospectively studied carbidopa/levodopa pharmacy errors in a cohort of PD outpatients. Over 1 year, pharmacy errors occurred in 8/73 (11%) subjects treated with this medication, producing adverse drug events (ADEs) in 7/8 (87.5%) and increased healthcare utilization in 6/8 (75%) cases. The most common errors were substitution of controlled-release for immediate-release carbidopa/levodopa 25/100 mg (5/8; 62.5%) or dispensation of the wrong carbidopa/levodopa dosage (2/8; 25%). All errors involved ongoing prescriptions, including three interpharmacy transfers. Three subjects (37.5%) questioned pharmacy staff about the change in appearance of the tablets, but the error was corrected in only 1/3 of these cases. Carbidopa/levodopa outpatient pharmacy errors are a common, preventable cause of morbidity and excessive healthcare utilization in PD. Education of healthcare providers, patients, and pharmacy staff is warranted to reduce these errors and associated ADEs. (C) 2010 Movement Disorder Society.
引用
收藏
页码:2867 / 2871
页数:5
相关论文
共 50 条
  • [1] Carbidopa/Levodopa Pharmacy Errors in Parkinson's Disease
    Khadem, Nasim R.
    Nirenberg, Melissa J.
    [J]. NEUROLOGY, 2010, 74 (09) : A350 - A350
  • [2] Levodopa/carbidopa/entacapone in Parkinson's disease
    Seeberger, Lauren C.
    Hauser, Robert A.
    [J]. EXPERT REVIEW OF NEUROTHERAPEUTICS, 2009, 9 (07) : 929 - 940
  • [4] Nanoencapsulation of Levodopa and Carbidopa for the Treatment of Parkinson's Disease
    Fan, Baochan
    Lamba, Sanvi
    Hu, Qiaobin
    Wang, Shu
    [J]. ANNALS OF NEUROLOGY, 2022, 92 : S118 - S119
  • [5] LEVODOPA WITH BENSERAZIDE OR CARBIDOPA IN PARKINSON DISEASE
    RINNE, UK
    MOLSA, P
    [J]. NEUROLOGY, 1979, 29 (12) : 1584 - 1589
  • [6] Duopa - A Carbidopa/Levodopa Enteral Suspension for Parkinson's Disease
    不详
    [J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2015, 57 (1474): : 112 - 112
  • [7] Brasofensine treatment for Parkinson's disease in combination with levodopa/carbidopa
    Frackiewicz, EJ
    Jhee, SS
    Shiovitz, TM
    Webster, J
    Topham, C
    Dockens, RC
    Whigan, D
    Salazar, DE
    Cutler, NR
    [J]. ANNALS OF PHARMACOTHERAPY, 2002, 36 (02) : 225 - 230
  • [8] Pharmacokinetics and pharmacodynamics of levodopa/carbidopa cotherapies for Parkinson's disease
    Mueller, Thomas
    [J]. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2020, 16 (05) : 403 - 414
  • [9] Adherence with levodopa/carbidopa/entacapone versus levodopa/carbidopa and entacapone as separate tablets in patients with Parkinson's disease
    Delea, Thomas E.
    Thomas, Simu K.
    Hagiwara, May
    Mancione, L.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (07) : 1543 - 1552
  • [10] Double-Blind Trial of Levodopa/Carbidopa/Entacapone Versus Levodopa/Carbidopa in Early Parkinson's Disease
    Hauser, Robert A.
    Panisset, Michel
    Abbruzzese, Giovanni
    Mancione, Linda
    Dronamraju, Nalina
    Kakarieka, Algirdas
    [J]. MOVEMENT DISORDERS, 2009, 24 (04) : 541 - 550